Sihuan Pharmaceutical Holdings Group Ltd. (HKG:0460)
Hong Kong
· Delayed Price · Currency is HKD 1.290
-0.020 (-1.53%)
Apr 29, 2026, 4:08 PM HKT
HKG:0460 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,618 | 1,901 | 1,861 | 2,181 | 3,038 | Upgrade
|
| Revenue Growth (YoY) | 37.71% | 2.18% | -14.70% | -28.21% | 23.30% | Upgrade
|
| Cost of Revenue | 816.15 | 659.4 | 564.9 | 693.61 | 607.9 | Upgrade
|
| Gross Profit | 1,802 | 1,242 | 1,296 | 1,488 | 2,430 | Upgrade
|
| Selling, General & Admin | 1,118 | 1,175 | 911.22 | 1,023 | 1,129 | Upgrade
|
| Research & Development | 291.27 | 473.93 | 577.66 | 936.58 | 868.07 | Upgrade
|
| Other Operating Expenses | -84.24 | -41.67 | -52.69 | 63.72 | -242.74 | Upgrade
|
| Operating Expenses | 1,325 | 1,608 | 1,436 | 2,024 | 1,754 | Upgrade
|
| Operating Income | 476.72 | -366.03 | -140.54 | -536.05 | 676.2 | Upgrade
|
| Interest Expense | -201.58 | -274.93 | -269.34 | -211.18 | -117.35 | Upgrade
|
| Interest & Investment Income | 98.83 | 175.55 | 147.91 | 146.79 | 163.95 | Upgrade
|
| Earnings From Equity Investments | 11.61 | -15.23 | -53.62 | -80.88 | -158.58 | Upgrade
|
| Currency Exchange Gain (Loss) | -17.04 | 11.64 | -6.76 | -18.39 | -4.57 | Upgrade
|
| EBT Excluding Unusual Items | 368.53 | -469 | -322.35 | -699.7 | 559.64 | Upgrade
|
| Impairment of Goodwill | - | - | - | -8.76 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 31.43 | 28.12 | 153.02 | -279.36 | 8.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | 17.19 | 12.6 | 8.07 | 194.09 | 59.23 | Upgrade
|
| Asset Writedown | - | - | - | -1,329 | -131.3 | Upgrade
|
| Pretax Income | 417.16 | -428.29 | -161.26 | -2,123 | 496.01 | Upgrade
|
| Income Tax Expense | 231.75 | 43.26 | 96.43 | 196.79 | 253.12 | Upgrade
|
| Earnings From Continuing Operations | 185.4 | -471.55 | -257.69 | -2,320 | 242.89 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 36.3 | -10.12 | Upgrade
|
| Net Income to Company | 185.4 | -471.55 | -257.69 | -2,283 | 232.77 | Upgrade
|
| Minority Interest in Earnings | -5.71 | 254.89 | 203.67 | 368.36 | 183.74 | Upgrade
|
| Net Income | 179.7 | -216.66 | -54.02 | -1,915 | 416.51 | Upgrade
|
| Net Income to Common | 179.7 | -216.66 | -54.02 | -1,915 | 416.51 | Upgrade
|
| Net Income Growth | - | - | - | - | -12.01% | Upgrade
|
| Shares Outstanding (Basic) | 9,121 | 9,266 | 9,297 | 9,330 | 9,431 | Upgrade
|
| Shares Outstanding (Diluted) | 9,127 | 9,266 | 9,297 | 9,330 | 9,483 | Upgrade
|
| Shares Change (YoY) | -1.50% | -0.33% | -0.35% | -1.62% | 0.19% | Upgrade
|
| EPS (Basic) | 0.02 | -0.02 | -0.01 | -0.21 | 0.04 | Upgrade
|
| EPS (Diluted) | 0.02 | -0.02 | -0.01 | -0.21 | 0.04 | Upgrade
|
| EPS Growth | - | - | - | - | -12.20% | Upgrade
|
| Free Cash Flow | - | 173.18 | 74.14 | -355.97 | 64.28 | Upgrade
|
| Free Cash Flow Per Share | - | 0.02 | 0.01 | -0.04 | 0.01 | Upgrade
|
| Dividend Per Share | 0.019 | 0.019 | - | 0.033 | 0.013 | Upgrade
|
| Dividend Growth | 2.63% | - | - | 153.85% | -7.14% | Upgrade
|
| Gross Margin | 68.83% | 65.31% | 69.64% | 68.20% | 79.99% | Upgrade
|
| Operating Margin | 18.21% | -19.25% | -7.55% | -24.58% | 22.25% | Upgrade
|
| Profit Margin | 6.86% | -11.40% | -2.90% | -87.79% | 13.71% | Upgrade
|
| Free Cash Flow Margin | - | 9.11% | 3.98% | -16.32% | 2.11% | Upgrade
|
| EBITDA | 676.8 | -165.95 | 40.21 | -229.26 | 931.69 | Upgrade
|
| EBITDA Margin | 25.85% | -8.73% | 2.16% | -10.51% | 30.66% | Upgrade
|
| D&A For EBITDA | 200.08 | 200.08 | 180.75 | 306.79 | 255.49 | Upgrade
|
| EBIT | 476.72 | -366.03 | -140.54 | -536.05 | 676.2 | Upgrade
|
| EBIT Margin | 18.21% | -19.25% | -7.55% | -24.58% | 22.25% | Upgrade
|
| Effective Tax Rate | 55.55% | - | - | - | 51.03% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.